HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Deciphering trastuzumab resistance in residual tumor according to HER2 status after neoadjuvant trastuzumab containing regimen in HER2 positive breast cancer patients might help to choose further adjuvant anti-HER2 treatment.

AuthorsZohrab Abduyev, Kadri Altundag
JournalJournal of B.U.ON. : official journal of the Balkan Union of Oncology (J BUON) 2019 Sep-Oct Vol. 24 Issue 5 Pg. 2208 ISSN: 2241-6293 [Electronic] Cyprus
PMID31786900 (Publication Type: Letter)
Chemical References
  • Antineoplastic Agents, Immunological
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab
Topics
  • Antineoplastic Agents, Immunological (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Breast Neoplasms (drug therapy, metabolism, pathology)
  • Chemotherapy, Adjuvant
  • Drug Resistance, Neoplasm (drug effects)
  • Female
  • Humans
  • Neoplasm, Residual (drug therapy, metabolism, pathology)
  • Patient Selection
  • Receptor, ErbB-2 (metabolism)
  • Trastuzumab (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: